Literature DB >> 9103484

Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume.

C F Minto1, C Howe, S Wishart, A J Conway, D J Handelsman.   

Abstract

We studied healthy men who underwent blood sampling for plasma nandrolone, testosterone and inhibin measurements before and for 32 days after a single i.m. injection of 100 mg of nandrolone ester in arachis oil. Twenty-three men were randomized into groups receiving nandrolone phenylpropionate (group 1, n = 7) or nandrolone decanoate (group 2, n = 6) injected into the gluteal muscle in 4 ml of arachis oil vehicle or nandrolone decanoate in 1 ml of arachis oil vehicle injected into either the gluteal (group 3, n = 5) or deltoid (group 4, n = 5) muscles. Plasma nandrolone, testosterone and inhibin concentrations were analyzed by a mixed-effects indirect response model. Plasma nandrolone concentrations were influenced (P < .001) by different esters and injection sites, with higher and earlier peaks with the phenylpropionate ester, compared with the decanoate ester. After nandrolone decanoate injection, the highest bioavailability and peak nandrolone levels were observed with the 1-ml gluteal injection. Plasma testosterone concentrations were also influenced (P < .001) by the ester and injection site, with the most rapid, but briefest, suppression being due to the phenylpropionate ester, whereas the most sustained suppression was achieved with the 1-ml gluteal injection. Plasma inhibin concentrations were also significantly influenced by injection volume and site, with the lowest nadir occurring after the nandrolone decanoate 1-ml gluteal injection. Thus, the bioavailability and physiological effects of a nandrolone ester in an oil vehicle are greatest when the ester is injected in a small (1 ml vs. 4 ml) volume and into the gluteal vs. deltoid muscle. We conclude that the side-chain ester and the injection site and volume influence the pharmacokinetics and pharmacodynamics of nandrolone esters in an oil vehicle in men.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103484

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Significance of 19-norandrosterone in athletes' urine samples.

Authors:  C Ayotte
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

Review 2.  Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.

Authors:  Susan Weng Larsen; Claus Larsen
Journal:  AAPS J       Date:  2009-11-06       Impact factor: 4.009

Review 3.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 4.  Lipid-based drug carriers for prodrugs to enhance drug delivery.

Authors:  Jennica L Zaro
Journal:  AAPS J       Date:  2014-10-01       Impact factor: 4.009

5.  Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate.

Authors:  Gideon Sartorius; Carolyn Fennell; Sasa Spasevska; Leo Turner; Ann J Conway; David J Handelsman
Journal:  Asian J Androl       Date:  2010-02-01       Impact factor: 3.285

6.  Translational studies on a ready-to-use intramuscular injection of penethamate for bovine mastitis.

Authors:  I G Tucker; R Jain; F Alawi; K Nanjan; O Bork
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

7.  Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation.

Authors:  Shringi Sharma; Steve Caritis; Gary Hankins; Menachem Miodovnik; Mary F Hebert; Don Mattison; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2016-07-13       Impact factor: 4.335

Review 8.  Update on nandrolone and norsteroids: how endogenous or xenobiotic are these substances?

Authors:  V Bricout; F Wright
Journal:  Eur J Appl Physiol       Date:  2004-03-20       Impact factor: 3.078

Review 9.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

10.  Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option.

Authors:  Maria Gabriela Figueiredo; Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2022-02-17       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.